Iovance Biotherapeutics, Inc. logo IOVA - Iovance Biotherapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 15
HOLD 6
SELL 0
STRONG
SELL 0
| PRICE TARGET: $13.44 DETAILS
HIGH: $20.00
LOW: $5.00
MEDIAN: $15.00
CONSENSUS: $13.44
DOWNSIDE: 1.32%

Stock News

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 111,615 shares of Iovance's common stock to twenty-one new, non-executive employees.

Oct 16, 2026 01:15 PM • globenewswire.com
55,275 Shares of Iovance Biotherapeutics, Inc. $IOVA Purchased by Corient Private Wealth LP

55,275 Shares of Iovance Biotherapeutics, Inc. $IOVA Purchased by Corient Private Wealth LP

Corient Private Wealth LP purchased a new stake in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 55,275 shares of the biotechnology company's stock, valued at approximately $230,000. Other hedge funds have also modified their holdings

Oct 05, 2026 11:21 PM • defenseworld.net
Iovance: Buy Now Before Many Growth Catalysts Kick In

Iovance: Buy Now Before Many Growth Catalysts Kick In

Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports improving margins and narrowing losses. I project gross margins reaching 65–70%, although continued cash burn and potential dilution remain risks.

Oct 05, 2026 01:42 AM • seekingalpha.com
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026.

Oct 01, 2026 03:00 AM • globenewswire.com
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleukin.

Sep 29, 2026 03:00 AM • globenewswire.com
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains

Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains

Iovance Biotherapeutics (NASDAQ: IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Brian Gastman, Iovance's executive vice president of translational medicine and

Sep 20, 2026 01:03 AM • defenseworld.net
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance's common stock to eighteen new, non-executive employees.

Sep 18, 2026 01:10 PM • globenewswire.com
Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)

Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)

Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) and eXoZymes (NASDAQ: EXOZ - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Analyst Recommendations This is a breakdown of current ratings

Sep 16, 2026 11:32 PM • defenseworld.net
108,050 Shares in Iovance Biotherapeutics, Inc. $IOVA Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

108,050 Shares in Iovance Biotherapeutics, Inc. $IOVA Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 108,050 shares of the biotechnology company's stock, valued at approximately $449,000. Other large investors have

Sep 16, 2026 12:37 AM • defenseworld.net

Price Targets